Here, we discover the World Health Organization perspective on cannabidiol (CBD), including how there has been a shift in how CBD is socially perceived following reports and recommendations.
Investment Manager at the Ministry of Foreign Affairs of Denmark, Michael Prytz, charts the rapid development of the medical cannabis market in Europe and provides a look at the Danish model in this vein.
Laura Clews, Managing Associate at IP attorneys Mathys & Squire, analyses the protection for innovative new products in the medical cannabis & CBD sector.
Dr Nikos Xynos, PhD in Pharmaceutical Sciences/Natural Products Chemistry and MD a Nomad Labs, explores the various pathways to cannabinoid extraction, refining and purification technologies.
Following the first two articles that discussed the treatment of cancer and pain, this third piece will focus on the use of cannabinoids to treat psoriasis and rheumatoid arthritis.
Katharina Zedlacher, PR and communications at BioBloom GmbH, details the recent studies conducted to highlight how cannabinoid CBDa (cannabidiolic acid) increases bioavailability of CBD and its health-promoting properties.
David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health (NIH), shares his thoughts on closing gaps in cannabinoid research to make progress in pain management.
Paul McCourt, CEO and Founder of Celtic Wind Crops, outlines his vision for the future when it comes to how growing hemp in the local community can help a global crisis.
In the view of Amanda Feilding, Founder of the Beckley Foundation, “Psychedelics are unique pharmacological compounds that hold the promise of a profound paradigm shift in psychiatry.” Here, we learn about the Psychedelic Renaissance and the importance of drug policy reform.
